Skip to main content
67°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
489.10
+3.21 (+0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
February 14, 2025
Via
The Motley Fool
Exposures
Product Safety
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
February 13, 2025
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect.
Via
StockStory
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
February 12, 2025
Via
The Motley Fool
This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
February 12, 2025
Via
Benzinga
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
February 11, 2025
Via
Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
February 11, 2025
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.
Via
Investor's Business Daily
Vertex: Strong Sales, Stronger Pipeline
February 11, 2025
Via
The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
February 04, 2025
Via
Benzinga
Vertex Pharmaceuticals Unusual Options Activity
February 03, 2025
Via
Benzinga
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
February 11, 2025
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Via
StockStory
Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish
February 11, 2025
The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller.
Via
Stocktwits
Markets Steady, Positive; Q4 Earnings Keep Rolling
February 10, 2025
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warning signs may have been considered regarding President Trump’s 25% steel tariff headline...
Via
Talk Markets
Topics
Government
Stocks / Equities
World Trade
Exposures
Political
Tariff
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
February 10, 2025
VRTX earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Vertex's Revenue Surges but EPS Slips
February 10, 2025
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Via
The Motley Fool
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
February 10, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the...
Via
StockStory
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
February 10, 2025
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth potential. Stock has bullish technicals but risks remain.
Via
Benzinga
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
February 10, 2025
Via
Benzinga
US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst
February 10, 2025
U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.
Via
Benzinga
Topics
World Trade
Exposures
Tariff
Earnings Scheduled For February 10, 2025
February 10, 2025
Via
Benzinga
McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday
February 10, 2025
Stock futures up, focus on McDonald's, ON Semiconductor, VOXX, Rockwell Automation, Vertex Pharmaceuticals.
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in February
February 09, 2025
Via
The Motley Fool
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
February 09, 2025
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Via
StockStory
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades'
February 06, 2025
UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.
Via
Benzinga
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
February 04, 2025
Via
The Motley Fool
Exposures
Product Safety
3 Magnificent Stocks to Buy and Hold Forever
February 03, 2025
Via
The Motley Fool
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
February 02, 2025
Via
The Motley Fool
Exposures
Product Safety
What You Missed On Friday
February 02, 2025
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
Topics
Stocks / Equities
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
February 02, 2025
Via
The Motley Fool
Exposures
Product Safety
Small- To Mid-Cap Biotech Trades Poised For Gains
February 01, 2025
On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...
Via
Talk Markets
Topics
ETFs
Stocks / Equities
< Previous
1
2
3
4
5
6
7
8
9
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.